News | July 05, 2024
Cardiological Society of India releases first Indian guidelines for dyslipidemia management
Dyslipidemia is a critical risk factor for cardiovascular diseases
Dyslipidemia is a critical risk factor for cardiovascular diseases
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
PhytoSquene now available for clinical and commercial use
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Subscribe To Our Newsletter & Stay Updated
